Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021-Reference-Cited by-同舟云学术

Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021

Published:2021-09-07 Issue:10 Volume:33 Page:529-540
ISSN:1460-2377
Container-title:International Immunology
language:en
Short-container-title:

Author:

Xu Kun¹,Dai Lianpan¹²,Gao George F²

Affiliation:

1. Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Tropical Medicine and Laboratory Medicine, The First Affiliated Hospital, Hainan Medical University, Hainan 571199, China

2. CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China

Abstract

Abstract Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine development have taken place since the isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the release of the viral genome sequence. By 21 May 2021, 101 vaccines were under clinical trials, and published data were available for 18 of them. Clinical study results from some vaccines indicated good immunogenicity and acceptable reactogenicity. Here, we focus on these 18 vaccines that had published clinical data to dissect the induced humoral and cellular immune responses as well as their safety profiles and protection efficacy.

Funder

National Program on Key Research Project of China

Strategic Priority Research Program

National Natural Science Foundation of China

Special Fund for the Prevention and Control of COVID-19

China Postdoctoral Science Foundation

Youth Innovation Promotion Association

Publisher

Oxford University Press (OUP)

Subject

Immunology,General Medicine,Immunology and Allergy

Link